^
Association details:
Biomarker:BRCA2 mutation
Cancer:Cholangiocarcinoma
Drug:Lynparza (olaparib) (PARP inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C1 - Off-label
  (Approved for Pancreatic Cancer)
New
Title:

Lynparza approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers

Excerpt:
AstraZeneca and MSD’s Lynparza (olaparib) has been approved in Japan for the treatment of advanced ovarian, prostate and pancreatic cancers….The three approvals authorise Lynparza for:...maintenance treatment after platinum-based chemotherapy for patients with BRCAm curatively unresectable pancreas cancer.
Evidence Level:
Sensitive: C2 – Inclusion Criteria
New
Title:

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

Excerpt:
...somatic mutations in ATM, ATR, CHEK2, BRCA 1/2, RAD51, BRIP1, PALB2, PTEN, FANC, NBN, EMSY, MRE11, ARID1A] or germline mutations in the above genes....
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Alterations in DNA Damage Repair Genes in Primary Liver Cancer

Excerpt:
Herein, we explored eight BRCAness patients with seven ICC and 1 H-ChC, who were all treated with olaparib (a PARPi)...three patients who achieved partial response had germline BRCA2 mutations and family cancer history, highlighting that patients with ICC with BRCA2 germline mutations may be more sensitive to PARPi therapy.
DOI:
10.1158/1078-0432.CCR-19-0127
Trial ID:
Evidence Level:
Sensitive: C3 – Early Trials
New
Title:

Comprehensive molecular profiling of intrahepatic cholangiocarcinoma in the Chinese population and therapeutic experience

Excerpt:
Samples from 122 individual patients with ICC were analyzed….BRCA1/2 mutations were detected in 16 (13%) patients...Four patients accepted poly ADP-ribose polymerase (PARP) inhibitor (olaparib) treatment combined with chemotherapy. Two patients achieved stable disease, and two patients responded partially.
Secondary therapy:
Chemotherapy
DOI:
https://dx.doi.org/10.1186%2Fs12967-020-02437-2